ClinicalTrials.gg
TerminatedNCT03483077Updated Aug 10, 2022Results posted

This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.

A Phase 1 interventional study of BI 730460 and Placebo in Healthy, sponsored by Boehringer Ingelheim. Terminated at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Why this study was terminated
The trial was ended after completion of dose group 6 of the SRD part, in accordance with a predefined protocol discontinuation criteria. The planned bioavailability evaluation was not performed due to the sponsor's decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The primary objective of the single-rising dose (SRD) part (trial part 1) is to investigate the safety and tolerability of BI 730460 in healthy subjects following oral administration of single rising doses. The secondary objective is the exploration of the pharmacokinetics (PK) including dose proportionality, and pharmacodynamics of BI 730460 after single dosing.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 45 years (incl.)
  • (BMI) of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  • Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR) or (ECG)) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to the trial medication or its )
  • Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. /QTc interval prolongation)
  • Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on specified trial days
  • Alcohol abuse (consumption of more than 30 g per day for males)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms in males) or any other relevant Electrocardiogram (ECG) finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

In addition, the following trial-specific exclusion criteria apply:

  • Male subjects with women of (WOCBP) partner who are unwilling to use male (condom or sexual abstinence) from the first administration of trial medication until 30 days after last administration of trial medication
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
48 participants (actual)

Study arms

  • Placebo comparator
    Placebo matching BI 730460

    Placebo tablet(s) matching BI 730460 tablet(s) administered orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.

    Drug: Placebo

  • Experimental
    2 milligram (mg) - BI 730460

    A single dose of 2 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.

    Drug: BI 730460

  • Experimental
    8 mg - BI 730460

    A single dose of 8 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.

    Drug: BI 730460

  • Experimental
    25 mg - BI 730460

    A single dose of 25 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.

    Drug: BI 730460

  • Experimental
    50 mg - BI 730460

    A single dose of 50 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.

    Drug: BI 730460

  • Experimental
    100 mg - BI 730460

    A single dose of 100 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.

    Drug: BI 730460

  • Experimental
    200 mg - BI 730460

    A single dose of 200 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.

    Drug: BI 730460

Interventions

  • DrugBI 730460

    tablets

  • DrugPlacebo

    tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Drug-related Adverse Events

    Percentages are calculated using total number of participants per treatment as the denominator. MedDRA version used for reporting: 22.0.

    Time frame: From drug administration until end of trial, up to 13 days.

Secondary outcomes

  1. Area Under the Concentration-time Curve of BI 730460 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of BI 730460 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).

    Time frame: Within 3 hours (h) prior to drug administration followed by 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 34.0, 48.0, 72.0, 96.0, 168.0 hours post drug administration.

  2. Maximum Measured Concentration of BI 730460 in Plasma

    Maximum measured concentration of BI 730460 in plasma (Cmax).

    Time frame: Within 3 hours (h) prior to drug administration followed by 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 34.0, 48.0, 72.0, 96.0, 168.0 hours post drug administration.

07

Results

Posted Aug 10, 2022
Limitations and caveats
The trial was ended after completion of dose group 6 of the SRD part, in accordance with a predefined protocol discontinuation criteria. The planned bioavailability evaluation was not performed due to the sponsor's decision.

Participant flow

The evaluation of single-rising dose (SRD) of BI 730460 was designed as a partially randomised, single-blind, placebo-controlled trial and the evaluation of bioavailability of BI 730460 with and without food was designed as a randomised, open-label, single-dose, two-way cross-over trial.

Participant flow — Overall Study
MilestonePlacebo Matching BI 7304602 Milligram (mg) - BI 7304608 mg - BI 73046025 mg - BI 73046050 mg - BI 730460100 mg - BI 730460200 mg - BI 730460
Started12666666
Completed12666666
Not completed0000000

Outcome measures

PrimaryPercentage of Participants With Drug-related Adverse Events

Percentages are calculated using total number of participants per treatment as the denominator. MedDRA version used for reporting: 22.0.

Time frame:
From drug administration until end of trial, up to 13 days.
Reported as:
Number · Percentage of participants (%)
Percentage of Participants With Drug-related Adverse Events
Percentage of participants (%)Placebo Matching BI 7304602 Milligram (mg) - BI 7304608 mg - BI 73046025 mg - BI 73046050 mg - BI 730460100 mg - BI 730460200 mg - BI 730460
Percentage of Participants With Drug-related Adverse Events8.30.00.016.70.00.00.0
SecondaryArea Under the Concentration-time Curve of BI 730460 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of BI 730460 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).

Time frame:
Within 3 hours (h) prior to drug administration followed by 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 34.0, 48.0, 72.0, 96.0, 168.0 hours post drug administration.
Reported as:
Geometric mean · Nanomol*hour per litre
Area Under the Concentration-time Curve of BI 730460 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Nanomol*hour per litre2 Milligram (mg) - BI 7304608 mg - BI 73046025 mg - BI 73046050 mg - BI 730460100 mg - BI 730460200 mg - BI 730460
Area Under the Concentration-time Curve of BI 730460 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)557 ± 35.42540 ± 41.25610 ± 25.411200 ± 56.831500 ± 23.847600 ± 36.1
SecondaryMaximum Measured Concentration of BI 730460 in Plasma

Maximum measured concentration of BI 730460 in plasma (Cmax).

Time frame:
Within 3 hours (h) prior to drug administration followed by 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 34.0, 48.0, 72.0, 96.0, 168.0 hours post drug administration.
Reported as:
Geometric mean · nanomol per litre
Maximum Measured Concentration of BI 730460 in Plasma
nanomol per litre2 Milligram (mg) - BI 7304608 mg - BI 73046025 mg - BI 73046050 mg - BI 730460100 mg - BI 730460200 mg - BI 730460
Maximum Measured Concentration of BI 730460 in Plasma31.8 ± 23.2140 ± 34.01860 ± 23.8309 ± 11.8597 ± 22.61470 ± 32.2

Adverse events

Collected over Adverse events were collected from drug administration till end of trial, up to 13 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Matching BI 7304600/12 (0%)0/12 (0%)5/12 (41.7%)
2 Milligram (mg) - BI 7304600/6 (0%)0/6 (0%)0/6 (0%)
8 mg - BI 7304600/6 (0%)0/6 (0%)1/6 (16.7%)
25 mg - BI 7304600/6 (0%)0/6 (0%)3/6 (50%)
50 mg - BI 7304600/6 (0%)0/6 (0%)0/6 (0%)
100 mg - BI 7304600/6 (0%)0/6 (0%)1/6 (16.7%)
200 mg - BI 7304600/6 (0%)0/6 (0%)2/6 (33.3%)
Total on Treatment0/48 (0%)0/48 (0%)12/48 (25%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo Matching BI 7304602 Milligram (mg) - BI 7304608 mg - BI 73046025 mg - BI 73046050 mg - BI 730460100 mg - BI 730460200 mg - BI 730460Total on Treatment
DyspepsiaGastrointestinal disorders0/120/60/61/60/60/60/61/48
Vessel puncture site haematomaGeneral disorders0/120/60/61/60/60/60/61/48
NasopharyngitisInfections and infestations0/120/61/61/60/60/60/62/48
RhinitisInfections and infestations2/120/60/60/60/60/60/62/48
HeadacheNervous system disorders1/120/60/61/60/61/60/63/48
PresyncopeNervous system disorders1/120/60/60/60/60/61/62/48
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/120/60/60/60/60/61/61/48
HaematocheziaGastrointestinal disorders1/120/60/60/60/60/60/61/48
VomitingGastrointestinal disorders1/120/60/60/60/60/60/61/48
Medical device site reactionGeneral disorders1/120/60/60/60/60/60/61/48

Baseline characteristics

Treated set: Participants who received at least 1 dose of trial drug.

Age, Continuous
Age, Continuous(Years)Placebo Matching BI 7304602 Milligram (mg) - BI 7304608 mg - BI 73046025 mg - BI 73046050 mg - BI 730460100 mg - BI 730460200 mg - BI 730460Total
Mean33.0 ± 6.836.0 ± 5.330.3 ± 6.230.7 ± 8.534.7 ± 6.730.5 ± 4.733.7 ± 7.932.7 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Matching BI 7304602 Milligram (mg) - BI 7304608 mg - BI 73046025 mg - BI 73046050 mg - BI 730460100 mg - BI 730460200 mg - BI 730460Total
Female00000000
Male1266666648
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Matching BI 7304602 Milligram (mg) - BI 7304608 mg - BI 73046025 mg - BI 73046050 mg - BI 730460100 mg - BI 730460200 mg - BI 730460Total
Hispanic or Latino00000000
Not Hispanic or Latino1266666648
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Matching BI 7304602 Milligram (mg) - BI 7304608 mg - BI 73046025 mg - BI 73046050 mg - BI 730460100 mg - BI 730460200 mg - BI 730460Total
American Indian or Alaska Native00000000
Asian00000000
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000000
White1266666648
More than one race00000000
Unknown or Not Reported00000000
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Mar 2019, 5 months.

Results were first posted in Aug 2022, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Mar 29, 2018
StartActual
Oct 9, 2018
Primary completionActual
Mar 21, 2019
CompletionActual
Mar 21, 2019
Results first posted
Aug 10, 2022
Last update
Aug 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03483077
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Oct 9, 2018
Primary completion
Mar 21, 2019
Completion
Mar 21, 2019
Results posted
Aug 10, 2022
Last update
Aug 10, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion